Sugi Predict

Sugi Predict / Compounds / Atranorin

Atranorin

Atranorin

SCHEMBL1370191

COC(=O)c1c(C)cc(OC(=O)c2c(C)cc(O)c(C=O)c2O)c(C)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 8/20 1.00
▸ PTGES O14684 1/20 1.00
▸ PTPN1 P18031 1/20 1.00
▸ MAPT P10636 3/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ TDP1 Q9NUW8 2/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ CASP1 P29466 1/20 0.60
▸ USP2 O75604 1/20 0.58
▸ POLB P06746 3/20 0.49
▸ HPGD P15428 2/20 0.49
▸ GFER P55789 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ IDO1 P14902 2/20 0.45
▸ SLC37A4 O43826 2/20 0.45
▸ ACHE P22303 1/20 0.42
▸ GLO1 Q04760 1/20 0.40
▸ ERN1 O75460 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Atranorin SCHEMBL29929139 1.00 CYP3A4 (1.00) CYP3A4PTGESPTPN1MAPTKMT2A
Atranorin SCHEMBL29928953 1.00 CYP3A4 (1.00) CYP3A4PTGESPTPN1MAPTKMT2A
Atranorin SCHEMBL29929644 1.00 CYP3A4 (1.00) CYP3A4PTGESPTPN1MAPTKMT2A
SCHEMBL17451512 0.90 CYP3A4 (0.81) CYP3A4PTGESPTPN1MAPTKMT2A
SCHEMBL22887135 0.89 CYP3A4 (0.80) CYP3A4PTGESPTPN1MAPTKMT2A
Methyl Haematommate SCHEMBL28343741 0.88 CYP3A4 (0.77) CYP3A4PTGESPTPN1MAPTKMT2A
SCHEMBL21369176 0.85 CYP3A4 (0.74) CYP3A4PTGESPTPN1MAPTKMT2A
Baeomycesic Acid SCHEMBL18621794 0.81 CYP3A4 (0.84) CYP3A4PTGESPTPN1MAPTKMT2A
Baeomycesic Acid SCHEMBL30056385 0.81 CYP3A4 (0.84) CYP3A4PTGESPTPN1MAPTKMT2A
SCHEMBL18621793 0.81 CYP3A4 (0.68) CYP3A4PTGESPTPN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368695-A1 Atranorin biosynthesis gene derived from lichens and uses thereof INDUSTRY ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIV (KR) 2025-12-04 — — US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 — — US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 — — US claimed
WO-2022260402-A1 ATRANORIN BIOSYNTHESIS GENE DERIVED FROM LICHEN AND USE THEREOF 순천대학교 산학협력단 2022-12-15 — — WO claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 — — WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 — — WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 — — WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 — — WO claimed
CN-104245800-B Novel benzene polycarboxylic acid compound RD创新有限公司 2017-09-08 — — CN claimed
US-9644074-B2 Benzene polycarboxylic acid compounds and their use as drug RINNOVATION APS (DK) 2017-05-09 — — US claimed
WO-2013143549-A1 BENZENE POLYCARBOXYLIC ACID COMPOUNDS AND THEIR USE AS DRUG RDINNOVATION APS (DK) 2013-10-03 — — WO claimed
US-20110286927-A1 ATF4 Inhibitors and Their Use for Neural Protection, Repair, Regeneration, and Plasticity CORNELL UNIVERSITY (US) 2011-11-24 — — US claimed
WO-2009020601-A2 ATF4 INHIBITORS AND THEIR USE FOR NEURAL PROTECTION, REPAIR, REGENERATION, AND PLASTICITY CORNELL UNIVERSITY (US) 2009-02-12 — — WO claimed
WO-2008122038-A1 REGULATING AUTOPHAGY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2008-10-09 — — WO claimed
WO-2008109521-A2 METHOD OF TREATMENT USING ATRANORIN UNIVERSITY OF SOUTH FLORIDA (US) 2008-09-12 — — WO claimed
EP-1098641-A4 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA ST JUDE PHARMACEUTICALS INC (US) 2003-08-27 — — EP claimed
EP-1098641-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA Texas Pharmaceuticals, Inc. (US) 2001-05-16 — — EP claimed
WO-2000006143-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA TEXAS PHARMACEUTICALS, INC. (US) 2000-02-10 — — WO claimed
US-4663080-A REMOVAL OF ETHYL (CHLORO)HEMATOMMATE OR/AND ETHYL (CHLORO) ATRANORIN SHISEIDO COMPANY LTD. (JP) 1987-05-05 — — US claimed
EP-0202647-A2 A process of obtaining a hypo-allergenic moss oil SHISEIDO COMPANY LIMITED (JP) 1986-11-26 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB CYP3A4 3571/4885PTGES 1679/4885PTPN1 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.